| 000 | 00956 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517055449.0 | ||
| 264 | 0 | _c20160518 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/kev375 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVerschueren, Patrick | |
| 245 | 0 | 0 |
_aShould rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure? _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _cFeb 2016 |
||
| 300 |
_a197-8 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 |
_aRituximab _xtherapeutic use |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 55 _gno. 2 _gp. 197-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/kev375 _zAvailable from publisher's website |
| 999 |
_c25342186 _d25342186 |
||